Aripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2023-03-01 DOI:10.1097/WNF.0000000000000536

Saliha Baykal, Caner Mutlu

{"title":"Aripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism.","authors":"Saliha Baykal, Caner Mutlu","doi":"10.1097/WNF.0000000000000536","DOIUrl":null,"url":null,"abstract":"Objectives: This report discusses the emergence, clinical appearance, and treatment of the rare entity Capgras syndrome (CS) in an adolescent diagnosed with autism.Methods: After a brief introduction to the CS, we conduct a detailed description of the case and review, after a search on the PubMed database, the known pathophysiology, psychiatric disorders associated with the onset of this syndrome, and the management of CS.Results: Capgras syndrome generally emerges during the course of delusional disorder, schizophrenia, or mood disorders, and for reasons such as neurological, infectious, or endocrinological diseases, drug intoxications, or deprivation. We encountered no previous reports of CS developing during the course of autism. There are no prospective studies concerning the treatment of the syndrome. However, antipsychotic drug use is primarily recommended in treatment. Antipsychotic drug therapy was therefore planned for the treatment of delusion, a psychotic symptom, in this case. The atypical antipsychotic aripiprazole was used based on the presence of accompanying diagnosis of autism, and the patient's body mass index and age. A relatively high dose of aripiprazole was required for the first psychotic attack in our patient. However, a good level of response was achieved within the expected time frame. In addition, no marked adverse effects were observed.Conclusions: Aripiprazole seems to be an effective and well-tolerated antipsychotic drug in the treatment of CS accompanying autism.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 2","pages":"85-86"},"PeriodicalIF":0.8000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000536","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This report discusses the emergence, clinical appearance, and treatment of the rare entity Capgras syndrome (CS) in an adolescent diagnosed with autism.

Methods: After a brief introduction to the CS, we conduct a detailed description of the case and review, after a search on the PubMed database, the known pathophysiology, psychiatric disorders associated with the onset of this syndrome, and the management of CS.

Results: Capgras syndrome generally emerges during the course of delusional disorder, schizophrenia, or mood disorders, and for reasons such as neurological, infectious, or endocrinological diseases, drug intoxications, or deprivation. We encountered no previous reports of CS developing during the course of autism. There are no prospective studies concerning the treatment of the syndrome. However, antipsychotic drug use is primarily recommended in treatment. Antipsychotic drug therapy was therefore planned for the treatment of delusion, a psychotic symptom, in this case. The atypical antipsychotic aripiprazole was used based on the presence of accompanying diagnosis of autism, and the patient's body mass index and age. A relatively high dose of aripiprazole was required for the first psychotic attack in our patient. However, a good level of response was achieved within the expected time frame. In addition, no marked adverse effects were observed.

Conclusions: Aripiprazole seems to be an effective and well-tolerated antipsychotic drug in the treatment of CS accompanying autism.

查看原文本刊更多论文

阿立哌唑用于治疗被诊断为自闭症的青少年卡普格拉综合征。

目的:本报告讨论了一名被诊断为自闭症的青少年的罕见实体Capgras综合征(CS)的出现、临床表现和治疗。方法:在简要介绍了CS之后，我们对病例进行了详细的描述，并在PubMed数据库中检索了已知的病理生理学、与该综合征发病相关的精神障碍以及CS的治疗方法。结果:Capgras综合征通常出现在妄想障碍、精神分裂症或情绪障碍的过程中，以及神经、感染性或内分泌疾病、药物中毒或剥夺等原因。我们以前没有遇到过在自闭症过程中出现CS的报道。目前尚无关于该综合征治疗的前瞻性研究。然而，抗精神病药物的使用是主要的治疗建议。因此，在这种情况下，抗精神病药物治疗计划用于治疗妄想，一种精神病症状。非典型抗精神病药物阿立哌唑的使用是基于是否伴有自闭症的诊断，以及患者的体重指数和年龄。在我们的病人第一次精神病发作时，需要使用相对高剂量的阿立哌唑。然而，在预期的时间框架内取得了良好的反应。此外，没有观察到明显的不良反应。结论:阿立哌唑是一种有效且耐受性良好的抗精神病药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.